AstraZeneca's Bydureon achieves better glycaemic control than insulin glargine in type 2 diabetes

UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes in adult patients uncontrolle…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news